ArticleEuropean journal of rheumatology2022
Sitagliptin-induced Achilles enthesopathy: Case report and literature review.
Article in European journal of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achilles enthesopathy is a pain caused due to inflammation of the insertion area of the Achilles tendon on the posterosuperior aspect of the calcaneus. Sometimes, isolated Achilles enthesopathy can be occurred, while, mostly, it is observed with rheumatological diseases. We herein aimed to report a case presentation, sitagliptin-induced enthesopathy, and literature review on musculoskeletal manifestations of gliptins. A 63-year-old man was diagnosed with type II diabetes mellitus, recently started sitagliptin. After the sitagliptin administration, bilateral Achilles enthesopathy has emerged. Afterward, he was diagnosed with sitagliptin-induced enthesopathy, and it was stopped. Following the termination of sitagliptin, all signs and symptoms related to Achilles enthesopathy disappeared. Gliptin-induced enthesopathy was reported rarely. To the best of our knowledge, this is the second case of gliptin-induced Achilles enthesopathy in the literature. Gliptins might not innocent drugs about musculoskeletal disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.